The clinical potential of antiangiogenic fragments of extracellular matrix proteins.
AffiliationCancer Research UK Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractNeovasculature development is a crucial step in the natural history of a cancer. While much emphasis has been placed on proangiogenic growth factors such as VEGF, it is clear that endogenous angiogenesis inhibitors also have critical roles in the regulation of this process. Recent research has identified several cryptic fragments of extracellular matrix/vascular basement membrane proteins that have potent antiangiogenic properties in vivo. It has become apparent that many of these fragments signal via interactions with endothelial integrins, although multiple downstream effector pathways have been implicated and endostatin, the first non-collagenous domain of collagen XVIII, influences an intricate signalling network. The activity of these molecules in animal models suggests that they may have significant clinical activity; however, results of phase I/II trials with endostatin were disappointing. Many possible reasons can be found for the failure of these studies. Weaknesses in trial design, endostatin administration regimen and patient selection are identifiable, and importantly the lack of a clearly defined antiangiogenic mechanism for endostatin hindered assessment of biologically effective dose. Additionally, in vivo immunological and proteolytic function-neutralising mechanisms may have negated endostatin's actions. Lessons learned from these studies will aid the future clinical development of other antiangiogenic extracellular matrix protein fragments.
CitationThe clinical potential of antiangiogenic fragments of extracellular matrix proteins. 2005, 93 (9):967-72 Br. J. Cancer
JournalBritish Journal of Cancer
- Endostatin/collagen XVIII--an inhibitor of angiogenesis--is expressed in cartilage and fibrocartilage.
- Authors: Pufe T, Petersen WJ, Miosge N, Goldring MB, Mentlein R, Varoga DJ, Tillmann BN
- Issue date: 2004 Aug
- Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin.
- Authors: Folkman J
- Issue date: 2006 Sep 26
- Endostatin signaling and regulation of endothelial cell-matrix interactions.
- Authors: Wickström SA, Alitalo K, Keski-Oja J
- Issue date: 2005
- Collagen XVIII/endostatin structure and functional role in angiogenesis.
- Authors: Zatterstrom UK, Felbor U, Fukai N, Olsen BR
- Issue date: 2000 Apr
- Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases.
- Authors: Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkilä P, Rehn M, Sorsa T, Salo T, Pihlajaniemi T
- Issue date: 2005 Jul 15